Loading…
Medicus Pharma Ltd. is projected to rise to $0.3058 by 2027, a +2% move from its current price of $0.301. MDCX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.2825 | $0.301 | $0.3207 | 0.00% |
| Aug 6 | $0.2752 | $0.301 | $0.3292 | 0.00% |
| Aug 7 | $0.2697 | $0.301 | $0.3359 | 0.00% |
| Aug 8 | $0.2652 | $0.301 | $0.3416 | 0.00% |
| Aug 9 | $0.2613 | $0.301 | $0.3468 | 0.00% |
| Aug 10 | $0.2578 | $0.301 | $0.3515 | 0.00% |
| Aug 11 | $0.2546 | $0.301 | $0.3559 | 0.00% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.2546 | $0.301 | $0.3559 | 0.00% |
| Week 2 | $0.2375 | $0.301 | $0.3814 | -0.01% |
| Week 3 | $0.2252 | $0.301 | $0.4023 | -0.01% |
| Week 4 | $0.2153 | $0.301 | $0.4207 | -0.02% |
| Week 5 | $0.2069 | $0.3009 | $0.4377 | -0.02% |
| Week 6 | $0.1997 | $0.3009 | $0.4536 | -0.02% |
| Week 7 | $0.1932 | $0.3009 | $0.4687 | -0.03% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.
The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023.
The company was incorporated in 2008 and is headquartered in West Conshohocken, Pennsylvania.
Medicus Pharma Ltd. (MDCX) operates in the Healthcare sector and is positioned as a small biotech company focused on US clinical development programs. Its current price is $0.28 and its market cap is $15.86M, with a rank of 4725.
The overall price outlook, based on the provided year-by-year forecast, shows a path from a neutral start in 2026 to progressively higher average prices and sizable upside by 2050, with maximums reaching $3.25 and average gains reflected in a 405.1% ROI by 2050.
Forecasted averages rise from $0.28 in 2026 to $1.41 by 2050, with corresponding max values climbing and multiple years displaying bullish sentiment along the way.
A major floor 61.1% below — a decisive break under it would weaken the trend.
The nearest floor, 12.6% below — buyers have tended to step in here.
The nearest ceiling, 62.1% above — a clean break opens room to run.
A major ceiling 88.4% above — clearing it would confirm fresh momentum.
Key MDCX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MDCX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.2812 | Buy | $0.2883 | Buy |
| MA 10 | $0.3277 | Sell | $0.3158 | Sell |
| MA 20 | $0.3652 | Sell | $0.3455 | Sell |
| MA 50 | $0.367 | Sell | $0.3802 | Sell |
| MA 100 | $0.379 | Sell | $0.5375 | Sell |
| MA 200 | $1.04 | Sell | $0.9924 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 36.34 | Neutral |
| Stoch RSI (14) | 14.22 | Buy |
| CCI (20) | -133.79 | Sell |
| Williams %R (14) | -91.61 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -20.98 | Sell |
| Bollinger %B (20,2) | 0.10 | Neutral |
| Stochastic %K (14) | 8.39 | Buy |
| TRIX (15) | -0.49 | Sell |
| Awesome (5,34) | -0.10 | Sell |
| Ultimate (7,14,28) | 23.70 | Buy |
| Momentum (10) | -0.10 | Sell |
| Aroon Osc (25) | -88.00 | Sell |
| Hull MA (9) | 0.24 | Buy |
| ADX (14) | 16.01 | Neutral |
| ATR (14) | 0.02 | Info |
The 30-day technical picture is Bearish, with RSI14 at 40. The stock is trading below the SMA50 of $0.3694 and well below the SMA200 of $1.09, signaling a negative near-term trend.
The 30-day price range spans $0.1821 to $0.4306, with near-term support at $0.318 and resistance at $0.488. The current price of $0.28 sits under the near-term support and beneath the moving averages, suggesting continued downside risk in the near term.
Annualized volatility is 100%, indicating a high level of price fluctuations and risk for this asset.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.263 | $0.301 | $0.4086 | 0% | Neutral | |
| $0.2228 | $0.3058 | $0.4535 | +2% | Neutral | |
| $0.2298 | $0.3354 | $0.5308 | +11% | Neutral | |
| $0.3047 | $0.4687 | $0.7792 | +56% | Bullish | |
| $0.3109 | $0.5015 | $0.8683 | +67% | Bullish | |
| $0.2423 | $0.4085 | $0.7324 | +36% | Bullish | |
| $0.2512 | $0.4418 | $0.8169 | +47% | Bullish | |
| $0.2296 | $0.4205 | $0.7993 | +40% | Bullish | |
| $0.1933 | $0.3684 | $0.7181 | +22% | Bullish | |
| $0.2622 | $0.5193 | $1.04 | +73% | Bullish | |
| $0.2434 | $0.5408 | $1.19 | +80% | Bullish | |
| $0.5941 | $1.32 | $3.04 | +339% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.263 | $0.301 | $0.3934 | +0.00% |
| September 2026 | $0.2674 | $0.325 | $0.4122 | +7.98% |
| October 2026 | $0.2441 | $0.3008 | $0.3893 | -7.44% |
| November 2026 | $0.2366 | $0.295 | $0.3879 | -1.95% |
| December 2026 | $0.2431 | $0.3063 | $0.4086 | +3.83% |
Click any year to see its month-by-month MDCX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, MDCX could reach as high as $0.4086, with a base case around $0.301 and support toward $0.263 — roughly 0% from $0.301. A consolidation phase looks the most probable path here.
Expect MDCX to range from $0.2228 to $0.4535 through 2027. The $0.3058 average target implies a +2% move from current prices. That is up +2% on the projected 2026 average. Price action looks broadly range-bound.
The MDCX price prediction for 2028 points to an average of $0.3354 (low $0.2298, high $0.5308) — a potential gain of +11% on today's $0.301. A consolidation phase looks the most probable path here.
In 2029, MDCX is projected to trade between $0.3047 and $0.7792, averaging $0.4687 — a potential gain of +56% from today's $0.301. That is up +40% on the projected 2028 average. Momentum favours further upside here.
Medicus Pharma Ltd.'s 2030 outlook centres on $0.5015, within a $0.3109 to $0.8683 range. That is up +7% on the projected 2029 average. That marks a +67% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, MDCX could reach as high as $0.7324, with a base case around $0.4085 and support toward $0.2423 — roughly +36% from $0.301. Momentum favours further upside here.
Expect MDCX to range from $0.2512 to $0.8169 through 2032. The $0.4418 average target implies a +47% move from current prices. That is up +8% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The MDCX price prediction for 2033 points to an average of $0.4205 (low $0.2296, high $0.7993) — a potential gain of +40% on today's $0.301. Momentum favours further upside here.
In 2034, MDCX is projected to trade between $0.1933 and $0.7181, averaging $0.3684 — a potential gain of +22% from today's $0.301. That is -12% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
Medicus Pharma Ltd.'s 2035 outlook centres on $0.5193, within a $0.2622 to $1.04 range. That is up +41% on the projected 2034 average. That marks a +73% change versus current levels. Momentum favours further upside here.
By 2040, MDCX could reach as high as $1.19, with a base case around $0.5408 and support toward $0.2434 — roughly +80% from $0.301. Buyers look set to stay in control over this stretch.
Expect MDCX to range from $0.5941 to $3.04 through 2050. The $1.32 average target implies a +339% move from current prices. That is up +144% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in MDCX today (≈ 3,322.259136 MDCX) could be worth
$4,386.16
+$3,386.16 (+339%) by 2050 · US Dollar
Based on the average projected MDCX price of $1.32 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MDCXwould be worth at today's price.
$1,000 invested in MDCX on Jul 31, 2025 (≈ 406.504059 MDCX) would be worth
$122.36
-$877.64 (-87.8%) today · 0.12× · US Dollar
Based on a MDCX entry price of $2.46 vs. today's $0.301.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.37 | $813.51 | -18.6% |
| 1 month ago | $0.4 | $752.5 | -24.8% |
| 3 months ago | $0.285 | $1,056.14 | +5.6% |
| 6 months ago | $1.19 | $252.94 | -74.7% |
| 1 year ago | $2.46 | $122.36 | -87.8% |
| All time (1.7y) ago | $2.65 | $113.58 | -88.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MDCX forecast.
Our base-case forecast reaches $0.60 around 2050.
Implied market cap at $0.60: $33.99M
The multi-year forecast shows a bullish path for Medicus Pharma Ltd., with the average price rising from $0.28 in 2026 to $1.41 by 2050 and the maximums climbing to $3.25.
Key milestones include an avg of $0.3473 in 2028 (ROI 24%) and $0.4687 in 2029 (ROI 67.4%), followed by $0.4882 in 2030 (ROI 74.3%), and $0.5531 in 2035 (ROI 97.5%). By 2040 the average is $0.5667 and the max reaches $1.24, with a 102.4% ROI, culminating in 2050 with an average of $1.41 and a max of $3.25 (ROI 405.1%).
These figures are estimates, not guarantees, and actual results may differ. The forecast reflects changing conditions, market dynamics, and the evolving clinical development program trajectory.
Tap a question to reveal the answer.
Forecasted average price in 2030 is $0.4882 with a max of $0.8457 and a min of $0.3025, and an ROI of 74.3% in that year (sentiment BULLISH).
The 2026 forecast shows a neutral start (avg $0.28, ROI 0%), with a bullish trajectory in later years. By 2029 the avg is $0.4687 (ROI 67.4%), and by 2050 the avg is $1.41 with a max of $3.25 (ROI 405.1%), indicating substantial upside potential but with uncertainty and risk.
Yes. The forecast shows a max of $1.10 in 2035, and $1.24 in 2040, with a long-term max of $3.25 in 2050.
The current price is $0.28 and the market cap is $15.86M (rank 4725).
The 30-day range is $0.1821 to $0.4306. RSI14 is 40, with support at $0.318 and resistance at $0.488. The sentiment is BEARISH, and the stock is trading below the SMA50 ($0.3694) and SMA200 ($1.09).
Medicus Pharma Ltd. Community Discussion
0Share your Medicus Pharma Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.